WuXi AppTec is looking forward to this year’s American Association of Pharmaceutical Scientists (AAPS) annual meeting—known as “PharmSci 360″—on Oct. 17-20. PharmSci 360 is being held at the Pennsylvania Convention Center located in Philadelphia’s Center City district.
For the first time, AAPS will be conducted in a hybrid format—both online and in-person. AAPS will release more than 300 hours of pre-recorded programming to all registrants shortly before the meeting begins on Oct. 17. The in-person meeting will extend that programming with new sessions, available exclusively to those who are physically present.
The 2021 annual meeting will feature five distinct tracks that package cutting-edge science and thought leadership into separate themes. This year’s tracks include:
- Discovery & Basic Research
- Preclinical Development
- Bioanalytics
- Clinical Pharmacology
- Manufacturing & Analytical Characterization
- Formulation & Delivery
WuXi AppTec is taking advantage of the unique hybrid format by exhibiting in-person (booth #433), and virtually. WuXi AppTec is also planning to host a presentation and a post-show webinar in addition to presenting two posters.
Dr. Jing Shi is scheduled to present “The Unique Bioanalytical Needs of New Modalities” as part of the Bioanalytics track. Her talk will focus on the bioanalytical challenges and considerations for RNA-based drugs, bispecific antibodies and multi-domain protein therapeutics, prodrugs, gene and cell therapies, and fusion proteins. She will also discuss methods ranging from the conventional ligand binding assays and liquid chromatography-mass spectrometry assays to quantitative polymerase chain reaction or flow cytometry often used for oligonucleotides and cell and gene therapies.
Dr. Shi is a vice president in WuXi AppTec’s Laboratory Testing Division and the global head of bioanalysis. She has extensive experience in bioanalytical, biomarker, clinical monitoring, toxicology and cell line development, supporting drug development and lot release testing through pre-clinical, clinical and post-market phases. She also has in-depth knowledge of GLP, GMP, CLIA regulations and ICH guidelines.
Two WuXi AppTec researchers will also present posters during the annual meeting.
- Principal scientist and project manager, Dr. Liying Jiang, will present a poster titled, “Quantification of Various Types of Oligonucleotides in Plasma and Tissue Matrix by LC-MS/MS or LC-FLD.”
- Researcher and strategy leader, Jing Huang, will present a poster titled, “Determination of Modified Thymidine Phosphorylase Concentration and its Activity in Mouse Serum by LC-MS/MS.”
If you’re planning to attend in person or online, click the link to schedule a time to talk with a WuXi AppTec subject matter expert.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
